# Quality Gate Results -- Session 015, Cycle 1

**Session**: session-20260328-123317
**Target**: Percolation Threshold Theory x T Cell Infiltration in Solid Tumors
**Fields**: Statistical mechanics (bond percolation theory) x Tumor immunology (ECM-mediated immune exclusion)
**Date**: 2026-03-28
**Evaluator**: Quality Gate v5.4 (Opus)
**Hypotheses evaluated**: 5

---

## Overall Novelty Verification

**Search 1**: "percolation theory T cell infiltration tumor immune exclusion ECM"
Result: Zero papers apply percolation critical phenomena to T cell infiltration or immune exclusion. Extensive literature on ECM barriers to T cell migration exists, but none uses percolation theory framework.

**Search 2**: "bond percolation collagen crosslink immune cell migration tumor 2024 2025"
Result: No percolation theory applications found. Literature focuses on LOX/collagen crosslinking effects on stiffness and migration qualitatively.

**Prior art**: Ashworth et al. 2015 (PMID 25881025) -- confirmed real. Applied percolation as structural characterization tool for collagen scaffolds in tissue engineering, identifying "percolation diameter" for fibroblast invasion. NOT tumor immunology, NOT T cells, NOT critical phenomena (exponents, universality).

**Overall novelty verdict**: The cross-domain connection (percolation theory applied to T cell immune exclusion) is GENUINELY NOVEL. No published work makes this specific bridge. All 5 hypotheses share this novelty.

---

## Hypothesis 1: E1-H1 (EH1)

**Title**: Voronoi Tessellation of Tumor ECM Recovers 3D Percolation Universality Class, with LOX Crosslink Density Mapping to Bond Occupation Probability via a Calibrated Pore-Area Threshold of 4 um^2

**Self-reported**: Confidence 6/10, Groundedness 7/10

### 10-Point Rubric

| Check | PASS/FAIL | Evidence |
|-------|-----------|----------|
| A-B-C structure | PASS | Bond percolation (A) -> LOX crosslink density as bond occupation (B) -> immune exclusion phase transition (C). Clear chain. |
| Mechanism specificity | PASS | Names LOX, BAPN, PXS-5505, Voronoi tessellation, z~6-8, p_c~0.18-0.22, Harris criterion, d_w=2.878, alpha=0.695. Highly specific. |
| Falsifiable prediction | PASS | Multiple: (1) T cell infiltration vs crosslink density shows power-law onset with beta=0.41; (2) MSD exponent alpha=0.695 at criticality; (3) transition survives heterogeneity (Harris criterion); (4) dose-response for PXS-5505 shows sharp inflection. |
| Counter-evidence | PASS | Four specific risks: lattice abstraction, soft thresholds (Raab 2016), PK/PD complications, alternative barriers. Genuine and substantive. |
| Test protocol | PASS | Syngeneic tumor models (4T1, KPC), PXS-5505 at 10 doses, CD8+ IHC, pyridinoline assay, hydroxyproline. 6-12 months. Actionable. |
| Confidence calibration | PASS | 6-7/10. Reasoned: unification strengthens both components, Harris criterion resolves heterogeneity concern, but lattice abstraction remains fundamental. Appropriate. |
| Novelty (web-verified) | PASS | Zero published connections. Distinct from Ashworth 2015 on all four axes documented. |
| Groundedness score | PASS | 7/10. Most core claims are grounded; active percolation p_c and p(dose) model are parametric but flagged. |
| Language precision | PASS | Specific enough for both statistical physicists and tumor immunologists. |
| Per-claim verification | PASS with notes | See below |

### Per-Claim Grounding Verification

| Claim | Tag | Verification | Status |
|-------|-----|-------------|--------|
| p_c = 0.2488 simple cubic | GROUNDED: Wang 2013 PRE | Standard value, confirmed | VERIFIED |
| Wolf 2013: T cell arrest at 4 um^2 | GROUNDED | Confirmed: Wolf et al. 2013 JCB 201:1069 | VERIFIED |
| d_w = 2.878 for 3D percolation | GROUNDED: Bunde & Havlin; Grassberger | Wikipedia shows d_w = 2.28-2.31. See note. | UNCERTAIN |
| Harris criterion: nu > 2/d | GROUNDED: Harris 1974 | Confirmed. Standard result. | VERIFIED |
| nu = 0.88 for 3D percolation | GROUNDED: Stauffer & Aharony 1994 | Confirmed by multiple sources. | VERIFIED |
| beta = 0.41 for 3D percolation | GROUNDED | Confirmed: 0.41 +/- 0.01. | VERIFIED |
| Nicolas-Boluda 2021, eLife | GROUNDED | Confirmed: eLife 10:e58688. | VERIFIED |
| PXS-5505 pan-LOX inhibitor | GROUNDED | Confirmed in clinical trials. | VERIFIED |
| Tang/Trackman/Kagan 1983 JBC 258:4331 | GROUNDED | Confirmed: BAPN KI = 6 uM. | VERIFIED |
| Active percolation p_c ~ 0.21-0.24 | PARAMETRIC | Correctly flagged as 2D extrapolation. | VERIFIED (parametric) |
| Raab et al. 2016, Science | GROUNDED | Confirmed: nuclear envelope rupture. | VERIFIED |
| Saha et al. 2024, Soft Matter | GROUNDED | Confirmed: run-and-tumble particles. | VERIFIED |

**NOTE on d_w**: Wikipedia lists d_w = 2.28-2.31 for 3D percolation, differing from 2.878. The hypothesis corrects from Alexander-Orbach (3.8) to 2.878, which is an improvement, but may itself need correction to ~2.28-2.31. If d_w = 2.28, then alpha = 0.88 (not 0.695). Core framework survives; specific MSD prediction changes. Flagged as UNCERTAIN.

### Rubric Scores

| Dimension | Weight | Score |
|-----------|--------|-------|
| Mechanistic Specificity | 20% | 9 |
| Testability | 20% | 8 |
| Groundedness | 20% | 7 |
| Novelty | 15% | 9 |
| Cross-Domain Creativity | 10% | 9 |
| Counter-Evidence | 5% | 8 |
| Calibrated Confidence | 5% | 8 |
| Impact Potential | 5% | 8 |

**Composite**: 1.80 + 1.60 + 1.40 + 1.35 + 0.90 + 0.40 + 0.40 + 0.40 = **8.25**

### Impact Annotation
- **Application pathway**: drug target + diagnostic
- **Nearest applied domain**: Immuno-oncology / LOX inhibitor clinical trial design
- **Validation horizon**: near-term (existing tools)

### VERDICT: PASS

**Reason**: Genuinely novel connection with high mechanistic specificity, verified citations, falsifiable predictions, and actionable test protocol using drugs in clinical trials. d_w uncertainty does not invalidate framework. Strongest hypothesis in session.

---

## Hypothesis 2: E2-H2 (EH2)

**Title**: Two-Exponent Test for Active-Percolation Universality Class in Tumor ECM

**Self-reported**: Confidence 5/10, Groundedness 6/10

### 10-Point Rubric

| Check | PASS/FAIL | Evidence |
|-------|-----------|----------|
| A-B-C structure | PASS | Percolation universality (A) -> two-exponent measurement (B) -> T cell cluster distribution (C). |
| Mechanism specificity | PASS | Three universality classes with distinct (d_w, tau) pairs. Crossover length ~ 9 um. |
| Falsifiable prediction | PASS | tau = 2.31 +/- 0.15 across tumor types. Same slope on log-log. |
| Counter-evidence | PASS | Anisotropy, crossover length uncertainty, inter-particle correlations. |
| Test protocol | PASS | Multi-tumor cluster analysis from immunofluorescence. Pre-screen via variance. |
| Confidence calibration | PASS | 5/10 appropriate. |
| Novelty (web-verified) | PASS | No published percolation analysis of T cell spatial distributions. |
| Groundedness score | PASS | 6/10 appropriate. |
| Language precision | PASS | Precise for both fields. |
| Per-claim verification | PASS | See below |

### Per-Claim Grounding Verification

| Claim | Tag | Verification | Status |
|-------|-----|-------------|--------|
| tau = 2.31 for 3D | GROUNDED: "Jan & Stauffer 1998" | Value correct (Wikipedia: 2.313). Citation uncertain. | VALUE VERIFIED |
| d_f = 2.53 for 3D | GROUNDED | Wikipedia: 2.523-2.530. Correct. | VERIFIED |
| Fisher scaling form | GROUNDED | Standard percolation theory. | VERIFIED |
| l_crossover ~ 9 um | PARAMETRIC | Dimensional analysis. Flagged. | VERIFIED (parametric) |
| Universality across lattices | GROUNDED | Standard result. | VERIFIED |

**NOTE**: "Jan & Stauffer 1998" not individually confirmed. Value is established from Paul-Ziff-Stanley 2001, Ballesteros 1997, Mertens-Moore 2018. Imprecise attribution, not hallucination.

### Rubric Scores

| Dimension | Weight | Score |
|-----------|--------|-------|
| Mechanistic Specificity | 20% | 7 |
| Testability | 20% | 8 |
| Groundedness | 20% | 6 |
| Novelty | 15% | 9 |
| Cross-Domain Creativity | 10% | 8 |
| Counter-Evidence | 5% | 7 |
| Calibrated Confidence | 5% | 8 |
| Impact Potential | 5% | 7 |

**Composite**: 1.40 + 1.60 + 1.20 + 1.35 + 0.80 + 0.35 + 0.40 + 0.35 = **7.45**

### Impact Annotation
- **Application pathway**: measurement method
- **Nearest applied domain**: Quantitative tumor biology / spatial transcriptomics
- **Validation horizon**: near-term (existing tools)

### VERDICT: PASS

**Reason**: Well-conceived experimental framework converting the universality class assumption into a direct measurement. Two-exponent test is falsifiable and over-constrained. All values verified.

---

## Hypothesis 3: E3-H4 (EH3)

**Title**: Collagen I/III Ratio Tunes Percolation Threshold p_c via Effective Coordination Number z

**Note**: Dispatch prompt titles this as "Michaelis-Menten LOX Kinetics" but markdown text describes Col I/III ratio mechanism. Evaluating the markdown as canonical.

**Self-reported**: Confidence 5/10, Groundedness 6/10

### 10-Point Rubric

| Check | PASS/FAIL | Evidence |
|-------|-----------|----------|
| A-B-C structure | PASS | Coordination number z (A) -> Col I/III ratio determines z (B) -> different p_c per tumor type (C). |
| Mechanism specificity | PASS | Col I (50-200 nm, z~5-7), Col III (25-50 nm, z~3-4). p_c~1.5/z. Tumor predictions. |
| Falsifiable prediction | PASS | Col I/III independently predicts immune infiltration after controlling for total crosslink density. |
| Counter-evidence | PASS | z values inferred, correlated structure, confounding components. |
| Test protocol | PASS | 100+ tumor cohort + synthetic 3D matrices. 6-12 months. |
| Confidence calibration | PASS | 5/10 appropriate for parametric estimates. |
| Novelty (web-verified) | PASS | No published framework linking collagen type ratio to exclusion via coordination number. |
| Groundedness score | PASS | 6/10 appropriate. |
| Language precision | PASS | Clear for both fields. |
| Per-claim verification | PASS | See below |

### Per-Claim Grounding Verification

| Claim | Tag | Verification | Status |
|-------|-----|-------------|--------|
| Col I: 50-200 nm, stiff, parallel | GROUNDED: Shoulders & Raines 2009 | Confirmed: Ann Rev Biochem 78:929. | VERIFIED |
| Col III: thin, branched reticular | GROUNDED: Keene et al. 1987 | Confirmed. | VERIFIED |
| PDAC immune-cold | GROUNDED | Clinical consensus. | VERIFIED |
| Bethe lattice p_c ~ 1/(z-1) | GROUNDED | Exact for tree graphs. | VERIFIED |
| z estimates | PARAMETRIC | Correctly flagged. | VERIFIED (parametric) |
| Universality unchanged across topologies | GROUNDED | Standard. Only p_c changes. | VERIFIED |

### Rubric Scores

| Dimension | Weight | Score |
|-----------|--------|-------|
| Mechanistic Specificity | 20% | 7 |
| Testability | 20% | 8 |
| Groundedness | 20% | 6 |
| Novelty | 15% | 8 |
| Cross-Domain Creativity | 10% | 7 |
| Counter-Evidence | 5% | 7 |
| Calibrated Confidence | 5% | 8 |
| Impact Potential | 5% | 7 |

**Composite**: 1.40 + 1.60 + 1.20 + 1.20 + 0.70 + 0.35 + 0.40 + 0.35 = **7.20**

### Impact Annotation
- **Application pathway**: diagnostic + enabling_technology
- **Nearest applied domain**: Pathology / immuno-oncology biomarkers
- **Validation horizon**: near-term (existing tools)

### VERDICT: PASS

**Reason**: Corrects conceptual error from parent (universality class unchanged, only p_c shifts). The prediction that Col I/III ratio independently predicts immune exclusion is specific, falsifiable, testable with existing tools. All claims verified.

---

## Hypothesis 4: E4-H8 (EH4)

**Title**: TGF-beta Contact-Dependent Activation Generates Short-Range Correlated Percolation with p_c Shift, Predicting LOX Inhibitor / Anti-TGF-beta Synergy

**Self-reported**: Confidence 5/10, Groundedness 5/10

### 10-Point Rubric

| Check | PASS/FAIL | Evidence |
|-------|-----------|----------|
| A-B-C structure | PASS | Correlated percolation (A) -> TGF-beta correlated crosslinking (B) -> p_c shift and synergy (C). |
| Mechanism specificity | PASS | integrin alphav-beta6, LTBP, LOX, galunisertib, fresolimumab, Weinrib-Halperin criterion. |
| Falsifiable prediction | PASS | Bliss synergy index > 1; synergy correlates with decorrelation (Moran's I). |
| Counter-evidence | PASS | Pleiotropic TGF-beta, small p_c shift, heterogeneous activation, bistability. |
| Test protocol | PASS | 5x5 combination matrix, SHG, Moran's I. 6-12 months. |
| Confidence calibration | PASS | 5/10 appropriate. |
| Novelty (web-verified) | PASS | No percolation-based synergy mechanism published. |
| Groundedness score | PASS | 5/10 appropriate. |
| Language precision | PASS | Precise for both fields. |
| Per-claim verification | PASS with notes | Directional notation inconsistency noted. |

### Per-Claim Grounding Verification

| Claim | Tag | Verification | Status |
|-------|-----|-------------|--------|
| alphav-beta6 TGF-beta activation | GROUNDED: Munger 1999, Cell 96:319 | Confirmed. | VERIFIED |
| TGF-beta1 structure | GROUNDED: Shi 2011, Nature 474:343 | Confirmed. | VERIFIED |
| TGFB1-LOX axis | GROUNDED: Setargew 2021 | Confirmed (PMID 33513979). | VERIFIED |
| Weinrib & Halperin 1983 | GROUNDED | Confirmed: Phys Rev B 27:413. | VERIFIED |
| p_c shift from correlations | GROUNDED: Weinrib 1983 | Real phenomenon. Direction needs care. | PARTIALLY VERIFIED |
| TGF-beta range 10-30 um | Mixed | Activation mechanism grounded; exact range parametric. | PARTIALLY VERIFIED |
| Galunisertib, fresolimumab | GROUNDED | Real drugs. | VERIFIED |
| Weinrib-Halperin extended criterion | GROUNDED | Standard result. | VERIFIED |

**NOTE**: Directional notation tension between bond-occupation and pore-occupation perspectives. Physics is internally consistent upon careful reading. Confusing but not wrong.

### Rubric Scores

| Dimension | Weight | Score |
|-----------|--------|-------|
| Mechanistic Specificity | 20% | 7 |
| Testability | 20% | 7 |
| Groundedness | 20% | 6 |
| Novelty | 15% | 8 |
| Cross-Domain Creativity | 10% | 8 |
| Counter-Evidence | 5% | 8 |
| Calibrated Confidence | 5% | 8 |
| Impact Potential | 5% | 8 |

**Composite**: 1.40 + 1.40 + 1.20 + 1.20 + 0.80 + 0.40 + 0.40 + 0.40 = **7.20**

### Impact Annotation
- **Application pathway**: therapy
- **Nearest applied domain**: Combination immunotherapy / translational oncology
- **Validation horizon**: medium-term

### VERDICT: CONDITIONAL_PASS

**Reason**: Mechanistically sound with verified citations and clinically relevant prediction. Downgraded due to (1) directional notation inconsistency, (2) predicted p_c shift magnitude (0.01-0.05) may be below detection in vivo, and (3) pleiotropic TGF-beta effects make clean attribution extremely difficult.

---

## Hypothesis 5: E5-H6

**Title**: MT1-MMP Catalytic Half-Life of 18-24 Hours Defines a Circadian-Scale Dynamic Percolation Window

**Self-reported**: Confidence 4/10, Groundedness 5/10

### 10-Point Rubric

| Check | PASS/FAIL | Evidence |
|-------|-----------|----------|
| A-B-C structure | PASS | Dynamic percolation (A) -> MT1-MMP circadian oscillation (B) -> chronotherapy window (C). |
| Mechanism specificity | CONDITIONAL | Names MT1-MMP, Lafleur 2006, Remacle 2003. BUT 18-24 hr half-life is fabricated. |
| Falsifiable prediction | PASS | Anti-PD-1 at ZT0 vs ZT12: 2-fold difference. Testable in MC38 model. |
| Counter-evidence | CONDITIONAL | Does not acknowledge rapid endocytosis or published alternative chronotherapy mechanism. |
| Test protocol | PASS | MC38 tumors, ZT0 vs ZT12, 6 weeks. |
| Confidence calibration | PASS | 4/10 cautious but unaware of core fabrication. |
| Novelty (web-verified) | CONDITIONAL | Chronotherapy of anti-PD-1 published (Qian 2024 Cell). ECM angle novel but invalidated. |
| Groundedness score | FAIL | 5/10 too high. Should be 2-3/10 given fabrication. |
| Language precision | PASS | |
| Per-claim verification | FAIL | Fabricated MT1-MMP half-life. |

### Per-Claim Grounding Verification

| Claim | Tag | Verification | Status |
|-------|-----|-------------|--------|
| MT1-MMP surface half-life 18-24 hr | GROUNDED: "Lafleur 2006, Remacle 2003" | **FABRICATED**. MT1-MMP rapidly internalized in 5-30 min via clathrin. Neither paper reports 18-24 hr. Timescale reverse-engineered from desired circadian period. | **FABRICATED PROPERTY** |
| BMAL1/CLOCK regulation of MT1-MMP | Implied GROUNDED | **OVERSTATED**. MMP-14 shows some circadian control in fibroblasts/cartilage. Direct "phase-locking" not supported. | OVERSTATED |
| Sahimi 1995 dynamic percolation | GROUNDED | Book confirmed (1994 not 1995). | VERIFIED (minor year error) |
| Lafleur 2006 | GROUNDED | Paper exists. Describes rapid internalization. **MISREPRESENTED** as supporting 18-24 hr. | MISREPRESENTED |
| Remacle 2003 | GROUNDED | Paper exists. Describes endocytic recycling. **MISREPRESENTED**. | MISREPRESENTED |
| All derived quantities (A_p, tau_accessible, ZT0 prediction) | PARAMETRIC | Built on fabricated timescale. | INVALIDATED |

### Critical Issue: MT1-MMP Half-Life

The hypothesis depends on MT1-MMP surface half-life of 18-24 hours. This is wrong:
1. MT1-MMP undergoes rapid clathrin-mediated endocytosis within 5-30 minutes.
2. The endocytic recycling cycle is minutes to ~1 hour.
3. The 18-24 hr value appears reverse-engineered from desired circadian period.
4. Individual molecule surface half-life is not 18-24 hours even if steady-state levels vary circadianly.

### Rubric Scores

| Dimension | Weight | Score |
|-----------|--------|-------|
| Mechanistic Specificity | 20% | 5 |
| Testability | 20% | 6 |
| Groundedness | 20% | 3 |
| Novelty | 15% | 5 |
| Cross-Domain Creativity | 10% | 7 |
| Counter-Evidence | 5% | 4 |
| Calibrated Confidence | 5% | 5 |
| Impact Potential | 5% | 5 |

**Composite**: 1.00 + 1.20 + 0.60 + 0.75 + 0.70 + 0.20 + 0.25 + 0.25 = **4.95**

### VERDICT: FAIL

**Reason**: FABRICATED PROTEIN PROPERTY. MT1-MMP surface half-life is ~15-30 minutes (rapid endocytosis), NOT 18-24 hours. Cited papers (Lafleur 2006, Remacle 2003) describe rapid internalization and do NOT report 18-24 hr half-life. Dynamic percolation framework depends entirely on this fabricated timescale. Chronotherapy timing already published (Qian et al. 2024 Cell) through T cell circadian biology.

---

## META-VALIDATION Reflection

1. **Scoring uniformity**: E1-H1 (8.25), E2-H2 (7.45), E3-H4 (7.20), E4-H8 (7.20), E5-H6 (4.95). Gap reflects fabrication in E5-H6. Top 4 cluster at 7.2-8.25.

2. **Verdicts**: 3 PASS, 1 CONDITIONAL_PASS, 1 FAIL. FAIL driven by documented fabrication. CONDITIONAL_PASS reflects notation inconsistency and small effect size.

3. **d_w uncertainty**: If d_w = 2.28 (not 2.878), alpha = 0.88 (not 0.695). Changes specific prediction, not framework. PASS maintained with flag.

4. **E5-H6 FAIL warranted**: 15-30 min half-life cannot generate circadian-scale ECM oscillations.

5. **Domain expert view**: Statistical physicist: E1-E4 well-applied. Tumor immunologist: ECM-lattice mapping untested but acknowledged. Both: MT1-MMP half-life in E5-H6 is wrong.

### Search Budget: 35 web searches across 5 hypotheses (5-9 per hypothesis).

### Claim Verification Summary

- **E1-H1**: 14 claims. 11 VERIFIED, 1 UNCERTAIN (d_w), 2 other. No hallucinations.
- **E2-H2**: 7 claims. 6 VERIFIED, 1 citation uncertain (value correct). No hallucinations.
- **E3-H4**: 10 claims. All verified or verified as parametric. No hallucinations.
- **E4-H8**: 11 claims. 8 VERIFIED, 3 partially. No hallucinations.
- **E5-H6**: 8 claims. 3 VERIFIED (existence), 2 MISREPRESENTED, 1 FABRICATED, 2 other. 1 fabricated property.

---

## Summary Table

| ID | Title (short) | Composite | Verdict | Key Issue |
|----|---------------|-----------|---------|-----------|
| E1-H1 | Voronoi + LOX Bond Occupation | 8.25 | **PASS** | d_w uncertain; framework robust |
| E2-H2 | Two-Exponent Universality Test | 7.45 | **PASS** | Citation uncertain; value correct |
| E3-H4 | Col I/III Ratio -> p_c | 7.20 | **PASS** | z values parametric |
| E4-H8 | TGF-beta Correlated Percolation | 7.20 | **CONDITIONAL_PASS** | Notation issue; small effect |
| E5-H6 | MT1-MMP Circadian Percolation | 4.95 | **FAIL** | FABRICATED: MT1-MMP t1/2 ~min not hr |

**Passed quality gate**: 3 PASS + 1 CONDITIONAL_PASS = 4
**Failed quality gate**: 1 FAIL (E5-H6)
